Ropinirole for restless legs syndrome: a placebo-controlled crossover trial

Neurology. 2004 Apr 27;62(8):1405-7. doi: 10.1212/01.wnl.0000120672.94060.f1.

Abstract

The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cross-Over Studies
  • Dizziness / chemically induced
  • Dopamine Agonists / adverse effects
  • Dopamine Agonists / therapeutic use*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Indoles / adverse effects
  • Indoles / therapeutic use*
  • Male
  • Middle Aged
  • Nausea / chemically induced
  • Restless Legs Syndrome / drug therapy*
  • Treatment Outcome

Substances

  • Dopamine Agonists
  • Indoles
  • ropinirole